Volume 24, Number 10—October 2018
Research
Candida auris in Healthcare Facilities, New York, USA, 2013–2017
Table 3
Organism, no. isolated | Clinical laboratories’ identification system |
Wadsworth Center identification using MALDI-TOF MS, no. isolates‡ | |||
---|---|---|---|---|---|
API | VITEK 2 | VITEK MS† | Other | ||
Candida haemulonii, 38 |
36 |
1§ | C. auris, 35 | ||
1¶ |
C. haemulonii, 1; Candida duobushaemulonii, 1; Candida glabrata,1 |
||||
No identification, 13 |
2 |
2 |
9 |
C. auris, 11 | |
C. glabrata, 2 |
|||||
C. auris, 6 |
6§ |
C. auris, 5 | |||
C. duobushaemulonii, 1 |
|||||
Candida famata, 5 |
1 |
3 |
1# |
C. guilliermondii, 1; C. lusitaniae, 1; Candida parapsilosis, 2; Candida fermentati, 1 |
|
Candida glabrata, 1 |
1 |
C. glabrata, 1 |
|||
Candida guilliermondii, 1 |
1 |
C. guilliermondii, 1 |
|||
Candida lusitaniae, 1 |
1 |
C. lusitaniae, 1 |
|||
Candida sphaerica, 1 |
1 |
Saccharomyces cerevisiae, 1 |
|||
Cryptococcus laurentii, 1 |
1 |
Cryptococcus neoformans, 1 |
|||
C. neoformans, 1 |
1 |
S. cerevisiae, 1 |
|||
C. famata/C. guilliermondii, 1 |
1 |
C. parapsilosis, 1 |
|||
C. famata/C. parapsilosis, 1 |
1 |
C. parapsilosis, 1 |
|||
C. famata/C. parapsilosis/
Candida tropicalis, 1 |
1 |
C. parapsilosis, 1 |
|||
Candida dubliniensis/C. haemulonii, 1 |
1 |
C. glabrata, 1 |
|||
C. lusitaniae/Candida utiliz, 1 |
1 |
C. lusitaniae, 1 |
|||
Candia sphaerica/Rhodotorula glutinis/ Rhodotorula mucilaginosa/C. laurentii, 1 |
1 |
C. parapsilosis, 1 |
|||
Zygosaccharomyces bailii/C. sake/C. famata/Candida lipolytica, 1 |
1 |
C. glabrata, 1 |
|||
S. cerevisiae, 23 |
7 |
16 |
S. cerevisiae, 23 |
||
Trichosporon mucoides, 1 | 1 | T. mucoides, 1 |
*API, bioMérieux, Inc., Durham, NC, USA; MALDI-TOF MS, Bruker Daltonics, Inc., Billerica, MA, USA; VITEK 2, bioMérieux, Durham, NC, USA; VITEK MS, bioMérieux, Solna, Sweden. MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MS, mass spectrometry.
†No C. auris entry.
‡Research use only library was expanded in-house by adding 10 C. auris isolates comprising clades I–IV (CDC-AR bank, https://www.cdc.gov/drugresistance/resistance-bank/index.html) and 8 C. auris isolates from New York in 2016 comprising clades I and II.
§MALDI-TOF MS, research use only library with 3 C. auris entries.
¶BD Phoenix Automated Microbiology System (BD Diagnostics, Sparks, MD, USA).
#RapID YEAST PLUS System (Thermo Fisher Scientific, Waltham, MA, USA).
1Additional members of the workgroup are listed at the end of this article.